Cost-effectiveness and price threshold analysis of daraxonrasib versus chemotherapy for previously treated metastatic pancreatic ductal adenocarcinoma in China
Background Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a highly lethal malignancy with limited treatment options after first-line progression. Daraxonrasib (RMC-6236), a RAS(ON) inhibitor, has demonstrated clinical benefit in previously treated mPDAC patients in the RASolute 302 trial. However, its economic value in China remains uncertain. This study evaluated the cost-effectiveness of Daraxonrasib versus Chemotherapy in previously treated mPDAC. Methods A three-state partitioned survival model was developed to evaluate costs and health outcomes from the Chinese healthcare system perspective. Clinical inputs were derived from reconstructed individual patient data from the RASolute 302 randomized clinical trial, with long-term survival extrapolated using parametric survival models. Costs were estimated using China-specific healthcare resource utilization and medical service prices. Outcomes included costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). A 10-year time horizon with an annual discount rate of 4.5% was applied. Deterministic sensitivity analyses, probabilistic sensitivity analyses, and price scenario analyses were performed. Results Compared with chemotherapy, the model estimated that daraxonrasib generated an additional 0.30 QALYs (0.98 vs. 0.68 QALYs) at an increased cost of US$38,125.89 (US$44,844.71 vs. US$6,718.82), resulting in an ICER of US$127,020.77 per QALY gained, which exceeded the Chinese willingness-to-pay threshold. Sensitivity analyses identified the acquisition cost of daraxonrasib, rather than chemotherapy drug costs, as the most influential determinant of cost-effectiveness. Price threshold analyses suggested that substantial price reductions would be required for daraxonrasib to approach the willingness-to-pay threshold. Conclusion From the perspective of the Chinese healthcare system, daraxonrasib provides additional clinical benefits for previously treated patients with mPDAC but is unlikely to be cost-effective compared with chemotherapy at the assumed price of US$5,000 per treatment cycle. Pricing strategies and reimbursement negotiations will be critical determinants of its potential economic value in China.
Authors
- Hui Lin (ORCID: https://orcid.org/0009-0007-8230-0152)
- Ruijia Chen (ORCID: https://orcid.org/0000-0002-2759-9290)
- Lixian Wu
- Chaoqi Li
- Qingna Jiang
- Kun Zhang
- Youting Chen
- Ruofei Wu
- Longlong Xu
- Minghai Fu
Institutions
- Fujian Medical University (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-11-12
- DOI
- https://doi.org/10.3389/fphar.2026.1930284
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00